Clinical trial Recruiting at 1 site Interventional Ages 7 to 14

Nightly external trigeminal nerve stimulation to reduce ADHD symptoms in children with autism

Official title: Phase IIa Clinical Trial of External Trigeminal Nerve Stimulation for Autistic Children With Attention Deficit/Hyperactivity Disorder

Run by University of California, San Francisco · NCT07214545 · Data updated 2026-11-12

This trial will test whether a small, nightly forehead patch that delivers external trigeminal nerve stimulation can reduce ADHD symptoms in children with autism.

Quick facts

Study typeInterventional
Ages7 Years to 14 Years
SexAll
Enrollment60 (estimated)
SponsorUniversity of California, San Francisco
Academic / other
Locations1 site (San Francisco, California)
StatusRecruiting
StartedOctober 6, 2025
Main results expectedSeptember 2027
Study endsJanuary 31, 2028
Registry record updatedOctober 20, 2026
Trial IDNCT07214545 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children with a clinician-confirmed DSM-5 diagnosis of autism, IQ above 70, a confirmed DSM-5 ADHD diagnosis with an ADHD-RS score over 24, stable medications for at least four weeks, and fluency in English for both child and caregiver.

Probably not a fit

Children with lower intellectual functioning (IQ ≤ 70), unstable major psychiatric conditions (for example current major depression, psychosis, or bipolar disorder), inability to tolerate or use the adhesive forehead device, or who cannot attend UCSF visits are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Children with clinician-confirmed autism and ADHD are randomly assigned to nightly active or sham external trigeminal nerve stimulation for about 8–12 weeks, with the option to try the active device later if they start on sham. Participation involves 4–5 in-person visits at UCSF plus four brief virtual check-ins, and nightly use of a small adhesive patch on the forehead while sleeping. Outcome measures include change in ADHD symptom scores, measures of core and associated autism features, cognitive testing, and tolerability/safety monitoring. The trial is designed as a randomized, blinded comparison of active versus sham stimulation to separate device effects from placebo and to gather short-term efficacy and safety data.

Why it matters

Potential benefit: If successful, this approach could provide a non-medication option that reduces ADHD symptoms and may improve some autism-related behaviors for some children.

How similar studies have gone: Earlier small trials of external trigeminal nerve stimulation have shown symptom improvements in pediatric ADHD, but evidence specifically in children with co-occurring autism is limited and still emerging.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Confirmed clinician diagnosis of ASD according to DSM-5 criteria, corroborated by prior testing (or obtained in study screening) with the Autism Diagnostic Observation Schedule (ADOS) with or without the Autism Diagnostic Interview-Revised (ADI-R)
* IQ \> 70 as corroborated by prior testing (or obtained in study screening) with the Wechsler Abbreviated Scale of Intelligence Scale (WASI)
* Confirmed diagnosis of ADHD according to DSM-5 criteria with minimum ADHD-RS score of \> 24
* Stable on current medications for a minimum of 4 weeks before baseline
* Ability to complete protocol testing
* Both the child participant and their primary caregiver must be fluent in English (speaking, reading, and understanding), as the questionnaires and assessment tools used in this study have been validated only in English.

Exclusion Criteria:

* Current major depression, history of psychosis, bipolar disorder, elevated risk of self-harm
* History of moderate to severe coarse brain injury
* Active medical illness expected to interfere with study assessments
* Presence of implanted stimulator (e.g., vagal nerve stimulator)
* Active dermatologic condition likely to interfere with eTNS electrode wearability
* Sleep disorder likely to interfere with nightly eTNS in the opinion of the study physician
* Inability to communicate discomfort or pain
* Current and anticipated continued use of antipsychotic or stimulant medication

Where it's running

  • UCSF Nancy Friend Pritzker Psychiatry Building
    San Francisco, California, United States
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.